Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The U.S. Meals and Drug Administration (FDA) has granted Regenerative Medication Superior Remedy (RMAT) designation to KB707, an investigational inhaled immunotherapy being...
Lengthy-term outcomes from the CATNON trial confirmed that including adjuvant temozolomide after radiotherapy considerably improved survival for sufferers with newly recognized IDH-mutant,...
In an interview for CURE Educated Affected person® Updates, Drs. Alexandra Miller, Daniel Orringer and Jonathan Yang mentioned how understanding analysis, biomarker...
